Janssen, “Partnership with Hanmi is still strong, and it’s only suspended, not terminated”

Published: 2016-12-12 10:05:03

Updated: 2016-12-12 10:05:03

“Hanmi Pharm and Janssen’s partnership is still strong, and we hope to continue the clinical trial as soon as possible,” Janssen which owns the license of HM12525A, a Hanmi Pharm’s obesity and diabetes treatment, announced through a pharmaceutical medium, Endpoints News, on the 8^th(Korean time).

When it came to the action of ‘Suspended participant recruitment’ on the clinical trial that is bei...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.